Novo Nordisk A/S
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novo Nordisk A/S sits in the top decile of US sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count).
Novo Nordisk A/S: 431 sponsored US clinical trials, 34 recruiting.
Novo Nordisk A/S sponsors 431 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 342 completed. 243 of these trials are in Phase 3-4 (later-stage) and 155 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 48 trials.
Top-decile sponsor footprint
Novo Nordisk A/S ranks in the top decile of sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
342 of 363 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
431 total, page 4 of 9
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT04074161
Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People
NCT04059367
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
NCT04010786
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT03989232
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
NCT03987451
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
NCT03926117
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
NCT03811535
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
NCT03922750
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
NCT03951805
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047
Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
NCT03816761
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
NCT03799198
A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
NCT03787225
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
NCT03741881
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
NCT03751657
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
NCT03707990
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03693430
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
NCT03687827
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
NCT03660774
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
NCT03661879
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
NCT03617081
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
NCT03611582
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03600480
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
NCT03596450
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
NCT03574584
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548987
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
NCT03548935
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
NCT03528551
A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity
NCT03479892
Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)
NCT03430154
Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity
NCT03308721
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
NCT03268005
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
NCT03196297
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
NCT03196284
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
NCT03095807
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
NCT03086330
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
NCT03136484
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
NCT03078478
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
NCT03075670
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
NCT02964247
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT02963922
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
NCT02963935
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
NCT03021187
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
NCT02994407
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716
First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity
NCT03015207
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 61 |
| Phase 3 | 220 |
| Phase 4 | 23 |
Therapeutic Areas
Where Novo Nordisk A/S enrollment is open (later-stage tilt)
34 recruiting of 431 indexed (8% open); 342 completed (79%).
Phase mix: 243 late (III/IV) vs 155 early (I/II) (later-stage heavy).
Top condition: Diabetes Mellitus, Type 2 (48 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novo Nordisk A/S: open-pipeline peers nationwide
Peers matched on 431 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 431 trials (± recruiting share)
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Dartmouth-Hitchcock Medical Center · 427 trials · 12% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Boston Scientific Corporation · 8% recruiting · 280 trials
- United Therapeutics · 8% recruiting · 63 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
Related
What to do with this Novo Nordisk A/S page
431 registered trials is a research-attention snapshot, not an endorsement of Novo Nordisk A/S or any single study.
- 34 of Novo Nordisk A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 2 is the condition Novo Nordisk A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novo Nordisk A/S pipeline card: 431 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.